Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 177

Sort by

Sort Order Select

Journal Articles

The Tumor Associated Antigen PRAME Exhibits Dualistic Functions That Are Targetable in Diffuse Large B-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-141168

Published: 2020

Journal Articles

Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R 2 -CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients with Previously Untreated Activated B-Cell (ABC)-Type Diffuse Large B-Cell Lymphoma (DLBCL): Health-Related Quality of Life (HRQoL) Analysis of the International Robust Study

Blood (2019) 134 (Supplement_1): 3475.

https://doi.org/10.1182/blood-2019-123948

Published: 2019

Journal Articles

Mutations Affecting RNA Binding Proteins Are a Novel Feature of Mantle Cell Lymphoma

Blood (2019) 134 (Supplement_1): 1478.

https://doi.org/10.1182/blood-2019-129136

Published: 2019

Journal Articles

Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies

Blood (2019) 134 (Supplement_1): 4092.

https://doi.org/10.1182/blood-2019-123083

Published: 2019

Journal Articles

TP53 Expression Correlates with TP53 Mutations and Is an Independent Predictor of Clinical Outcome in Patients with DLBCL Treated with R-CHOP

Pedro Farinha, MD PhD, Daisuke Ennishi, MD PhD, Anja Mottok, MD PhD, Susana Ben-Neriah, BSc, Barbara Meissner, PhD, Merrill Boyle, BSc, Jeffrey W. Craig, MD PhD, Graham W Slack, MD, Diego Villa, MD MPH, Kerry J Savage, BSc, MD MSc, Laurie H Sehn, MD, Ryan D. Morin, PhD, Marco A. Marra, PhD, Joseph M. Connors, MD, Randy D. Gascoyne, MD, Christian Steidl, MD, David W. Scott, MBChB, PhD

Blood (2019) 134 (Supplement_1): 3964.

https://doi.org/10.1182/blood-2019-121943

Published: 2019

Journal Articles

Molecular Correlates of Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma

Robert Kridel, MDMPH,PhD, Keren Isaev, MSc, Daisuke Ennishi, MD PhD, Brian Skinnider, MD, Karen Mungall, PhD, Andrew J. Mungall, PhD, Mehran Bakhtiari, MSc, Rosemarie Tremblay-Lemay, MD MSc, FRCPC, Barbara Meissner, PhD, Susana Ben-Neriah, BSc, Merrill Boyle, BSc, Diego Villa, MD MPH, Marco A. Marra, PhD, Christian Steidl, MD, Randy D. Gascoyne, MD, Kerry J Savage, BSc, MD MSc, David W. Scott, MBChB, PhD

Blood (2019) 134 (Supplement_1): 2763.

https://doi.org/10.1182/blood-2019-124235

Published: 2019

Journal Articles

Diffuse Large B-Cell Lymphomas with a Molecular PMBCL Expression Signature Represent a Distinct Molecular Subtype Associated with Poor Clinical Outcome

Gerben Duns, PhD, Elena Viganò, PhD, Daisuke Ennishi, MD PhD, Clementine Sarkozy, MD, Stacy Hung, Elizabeth Chavez, Katsuyoshi Takata, MD PhD, Anja Mottok, MD PhD, Randy D. Gascoyne, MD, Ryan D. Morin, PhD, Kerry J Savage, BSc, MD MSc, David W. Scott, MBChB, PhD, Christian Steidl, MD

Blood (2019) 134 (Supplement_1): 922.

https://doi.org/10.1182/blood-2019-131450

Published: 2019

Journal Articles

Molecular Features of Primary Central Nervous System Lymphoma in a Large Tissue Microarray

Diego Villa, MD, Graham W Slack, MD PhD, Muntadhar Al-Moosawi, MD, Susana Ben-Neriah, BSc, Tamara Shenkier, MD, Joseph M. Connors, MD, Laurie H Sehn, MDMPH, Kerry J Savage, BSc, MD MSc, David W. Scott, PhDMD,FRACP,FRCPA, Christian Steidl, MD, Randy D. Gascoyne, MD, King Tan, MD

Blood (2018) 132 (Supplement 1): 348.

https://doi.org/10.1182/blood-2018-99-114218

Published: 2018

Journal Articles

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Francesco d'Amore, MD, Sirpa Leppä, MD, Maria Gomes da Silva, MD PhD, Thomas Relander, Grete Fossum Lauritzsen, Peter De Nully Brown, Antonio Pezzutto, Jeanette K. Doorduijn, MD PhD, Eckhart Weidmann, Michel van Gelder, Achiel Van Hoof, Ilse Christiansen, Unn Merete Fagerli, MD PhD, Hans Hagberg, MD, P.J. Lugtenburg, Jan Walewski, Ka Lung Wu, Hilde Maria Demuynck, Rob Fijnheer, Jacob H. Christensen, Milada Jankovská, MD, Pär L. Josefsson, Hanneke Kluin-Nelemans, Jose Mario Mariz, MD, Mats A. Merup, Thomas Noesslinger, Eric Van Den Neste, Josée M Zijlstra, MD, Georg Hopfinger, MD, VIT Prochazka, MD, Esa Jantunen, MD PhD, Ludmila Boudova, Jose Cabecadas, Andreas Chott, Jan M.A. Delabie, MD PhD, Laurence de Leval, MD, Arjan Diepstra, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Peter Noergaard, Andreas Rosenwald, Grzegorz Rymkiewicz, Christer Sundström, Lorenz Truemper, MD, Gerald Wulf, MD, Lauren Chong, MSc, Alyssa Bouska, PhD, Lynette Smith, Christian Gisselbrecht, Marita Ziepert, PhD, Markus Loeffler, MD, Knut Liestol, Christian Steidl, MD, Randy D. Gascoyne, MD, David W. Scott, PhDMD,FRACP,FRCPA, Bettina Altmann, PhD, Javeed Iqbal, §, Wing C Chan, MD, Helle Toldbod, MS,PhD

Blood (2018) 132 (Supplement 1): 998.

https://doi.org/10.1182/blood-2018-99-110429

Published: 2018

Journal Articles

The Double-Hit Gene Expression Signature Defines a Clinically and Biologically Distinct Subgroup within GCB-DLBCL

Blood (2018) 132 (Supplement 1): 921.

https://doi.org/10.1182/blood-2018-99-116827

Published: 2018

Journal Articles

Somatic PRAME Deletions Are Associated with Decreased Immunogenicity, Apoptosis Resistance and Poor Outcomes in Diffuse Large B-Cell Lymphoma

Katsuyoshi Takata, MD PhD, Daisuke Ennishi, MDPhD, Ali Bashashati, Saeed Saberi, Elena Viganò, PhD, Shannon Healy, PhD, Julie S Nielsen, Gianluca D' Antonio, Brad H Nelson, Sohrab P Shah, Joseph M Connors, Randy D. Gascoyne, MD, David W. Scott, PhDMD,FRACP,FRCPA, Christian Steidl, MD

Blood (2018) 132 (Supplement 1): 667.

https://doi.org/10.1182/blood-2018-99-113516

Published: 2018

Journal Articles

Recurrent IL4R Somatic Mutations in Diffuse Large B-Cell Lymphoma Lead to an Altered Gene Expression Profile and Changes in Tumor Microenvironment Composition

Elena Viganò, PhD, Gerben Duns, PhD, Daisuke Ennishi, MDPhD, Randy D. Gascoyne, MD, Ryan D. Morin, PhDBSc,MSc, David W. Scott, PhDMD,FRACP,FRCPA, Christian Steidl, MD

Blood (2018) 132 (Supplement 1): 669.

https://doi.org/10.1182/blood-2018-99-110473

Published: 2018

Journal Articles

A Longitudinal Toxicity over Time (ToxT) Analysis of Bortezomib When Added to Bendamustine-Rituximab (BR) in Previously Untreated High Risk (HR) Follicular Lymphoma (FL) from in E2408

Fangxin Hong, PhD, Andrew M. Evens, DO, MSc, Paul J Novotny, M.S., Thomas M. Habermann, MD, Ranjana H Advani, MD, Randy D. Gascoyne, MD, Thomas E. Witzig, MD, Andrew Quon, MD, Erik A. Ranheim, MD PhD, Amylou C. Dueck, PhD, Brad S Kahl, MD, Gita Thanarajasingam, MD

Blood (2018) 132 (Supplement 1): 4157.

https://doi.org/10.1182/blood-2018-99-117249

Published: 2018

Journal Articles

UBR5 Mutations in Mantle Cell Lymphoma Lead to Increased Proliferation through a Cyclin D1-Dependent Mechanism

Olga Kutovaya, PhD, Stacy Hung, Elena Viganò, PhD, Adele Telenius, Bruce W Woolcock, Barbara Meissner, PhD, Shane Colborne, BSc, Randy D. Gascoyne, MD, Diego Villa, MD, Ryan D. Morin, PhD, BSc, MSc, David W. Scott, PhD MD, FRACP, FRCPA, Gregg B Morin, PhD, Christian Steidl, MD

Blood (2018) 132 (Supplement 1): 2849.

https://doi.org/10.1182/blood-2018-99-118524

Published: 2018

Journal Articles

Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 As a Therapeutic Target for Restoring MHC Expression in Diffuse Large B-Cell Lymphoma

Blood (2018) 132 (Supplement 1): 1560.

https://doi.org/10.1182/blood-2018-99-112010

Published: 2018

Journal Articles

The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E2408, the Bortezomib Induction or Novel Imid® Continuation (BIONIC) Study

Lucia Baratto, MD, Opeyemi Jegede, PhD, Fangxin Hong, PhD, Thomas M. Habermann, MD, Ranjana Advani, MD, Randy D. Gascoyne, MD, Lale Kostakoglu, MD, Thomas E. Witzig, MD, Erik A. Ranheim, MD PhD, Brad S Kahl, MD, Andrew Quon, MD, Andrew M. Evens, DO, MSc

Blood (2018) 132 (Supplement 1): 1615.

https://doi.org/10.1182/blood-2018-99-113247

Published: 2018

Journal Articles

Single-Cell Profiling Reveals Distinct Tumor Subtypes and Their Associated T-Cell Environments in Follicular Lymphoma

Xuehai Wang, PhD, Deanne Gracias, BSc, Michael Nissen, PhD, Elizabeth Chavez, BSc, Cg RT, Gabriela Cristina Segat, MSc, Manabu Kusakabe, MD PhD, Guillermo Simkin, PhD, Stepen Grinek, PhD, Tomohiro Aoki, MD PhD, Andrew Tran Thien-An Nguyen, Randy D. Gascoyne, MD, David W. Scott, PhDMD,FRACP,FRCPA, Ryan Brinkman, PhD, Christian Steidl, MD, Andrew P. Weng, MD

Blood (2018) 132 (Supplement 1): 1577.

https://doi.org/10.1182/blood-2018-99-114182

Published: 2018

Journal Articles

A 3-Arm Randomized Phase II Trial with Bendamustine/Rituximab Therapy in Untreated High Risk (HR) Follicular Lymphoma (FL): Bortezomib Induction or Novel IMiD ® Continuation (BIONIC) Study from the ECOG-ACRIN Cancer Research Group

Andrew M Evens, DO,MSc, Fangxin Hong, PhD, Thomas M Habermann, MD, Ranjana H. Advani, MD, Randy D. Gascoyne, MD, Thomas E Witzig, MD, Andrew Quon, MD, Erik A. Ranheim, MD PhD, Puneet Cheema, MD, Philip Dy, MD, Timothy E. O'Brien, MD, Jane N. Winter, MD, Terrence Paul Cescon, Julie Chang, MD, Brad S Kahl, MD

Blood (2017) 130 (Supplement 1): 482.

https://doi.org/10.1182/blood.V130.Suppl_1.482.482

Published: 2017

Journal Articles

BCL2 Expression Identifies a Population with Unmet Medical Need in Previously Untreated (1L) Patients with DLBCL

Edith Szafer-Glusman, Franklin V. Peale, Jr., Guiyuan Lei, Anja Mottok, Pedro Farinha, Jill Ray, Thalia A. Farazi, Martin Kornacker, Mikkel Z. Oestergaard, Juan Liu, Randy D. Gascoyne, MD, Elizabeth Punnoose

Blood (2017) 130 (Supplement 1): 418.

https://doi.org/10.1182/blood.V130.Suppl_1.418.418

Published: 2017

Journal Articles

The Mutational Landscape and Immune Microenvironment of Primary Intestinal Follicular Lymphoma (PIFL)

Johannes Hellmuth, MD, Abner Louissaint, MD PhD, Monika Szczepanowski, PhD, Sarah Häbe, MD, Alessandro Pastore, MD, Annette M. Staiger, PhD, Sylvia Hartmann, Robert Kridel, Matthew D. Ducar, MS, Peter Koch, MD, Martin Dreyling, MD PhD, Martin-Leo Hansmann, MD, German Ott, MD, Andreas Rosenwald, MD, Randy D. Gascoyne, MD, David M. Weinstock, MD, Wolfgang Hiddemann, MD PhD, Wolfram Klapper, MD, Oliver Weigert, MD

Blood (2017) 130 (Supplement 1): 2735.

https://doi.org/10.1182/blood.V130.Suppl_1.2735.2735

Published: 2017

NARROW

The Tumor Associated Antigen PRAME Exhibits Dualistic Functions That Are Targetable in Diffuse Large B-Cell Lymphoma

Mutations Affecting RNA Binding Proteins Are a Novel Feature of Mantle Cell Lymphoma

Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies

TP53 Expression Correlates with TP53 Mutations and Is an Independent Predictor of Clinical Outcome in Patients with DLBCL Treated with R-CHOP

Molecular Correlates of Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphomas with a Molecular PMBCL Expression Signature Represent a Distinct Molecular Subtype Associated with Poor Clinical Outcome

Molecular Features of Primary Central Nervous System Lymphoma in a Large Tissue Microarray

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

The Double-Hit Gene Expression Signature Defines a Clinically and Biologically Distinct Subgroup within GCB-DLBCL

Somatic PRAME Deletions Are Associated with Decreased Immunogenicity, Apoptosis Resistance and Poor Outcomes in Diffuse Large B-Cell Lymphoma

Recurrent IL4R Somatic Mutations in Diffuse Large B-Cell Lymphoma Lead to an Altered Gene Expression Profile and Changes in Tumor Microenvironment Composition

A Longitudinal Toxicity over Time (ToxT) Analysis of Bortezomib When Added to Bendamustine-Rituximab (BR) in Previously Untreated High Risk (HR) Follicular Lymphoma (FL) from in E2408

UBR5 Mutations in Mantle Cell Lymphoma Lead to Increased Proliferation through a Cyclin D1-Dependent Mechanism

Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 As a Therapeutic Target for Restoring MHC Expression in Diffuse Large B-Cell Lymphoma

The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E2408, the Bortezomib Induction or Novel Imid® Continuation (BIONIC) Study

Single-Cell Profiling Reveals Distinct Tumor Subtypes and Their Associated T-Cell Environments in Follicular Lymphoma

A 3-Arm Randomized Phase II Trial with Bendamustine/Rituximab Therapy in Untreated High Risk (HR) Follicular Lymphoma (FL): Bortezomib Induction or Novel IMiD ® Continuation (BIONIC) Study from the ECOG-ACRIN Cancer Research Group

BCL2 Expression Identifies a Population with Unmet Medical Need in Previously Untreated (1L) Patients with DLBCL

The Mutational Landscape and Immune Microenvironment of Primary Intestinal Follicular Lymphoma (PIFL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only